论文部分内容阅读
目的 探讨多药耐药基因(MDRl)在小细胞肺癌化疗中的作用和地位。方法 采用逆转录-多聚酶链式反应技术(RT/PCR)和免疫细胞化学染色法,检测了32例(初治原发癌21例和复治转移癌11例)小细胞肺癌患者血液中的MDRlmRNA水平和多药耐药蛋白(P-170)的表达,并对两种方法进行了比较。结果 初治的原发癌MDRl基因阳性表达率为14.29％,P-170蛋白阳性表达为14.27％;复治转移癌的MDRl基因阳性表达率为72.73％,P-170蛋白阳性表达为63.64％(P<0.01),有显著性差异。MDRl的基因和蛋白两种而检测方法具有一定的一致性.以RT/PTR方法具有更强的敏感性。结论 复治转移癌组比初治组具有更普遍的抗药性,且主要是获得性抗药,MDRl基因表达可作为临床合理地制定化疗方案,预测化疗效果的重要参考指标。
Objective To investigate the role and status of multidrug resistance gene (MDR1) in chemotherapy of small cell lung cancer. Methods RT-PCR and immunocytochemical staining were used to detect MDR1 mRNA in 32 patients with primary small cell lung cancer (21 primary and 11 primary tumors) Level and multidrug resistance protein (P-170) expression, and the two methods were compared. Results The positive rate of MDR1 gene was 14.29% and the positive rate of P-170 protein was 14.27%. The positive rate of MDR1 gene was 72.73% and the positive rate of P-170 protein was 63.64% P <0.01), there are significant differences. MDRl gene and protein detection methods have some consistency.To RT / PTR method has a stronger sensitivity. Conclusions The remittent-metastatic cancer group has more general resistance than the primary treatment group and is mainly acquired drug resistance. MDR1 gene expression can be used as an important reference index for predicting the efficacy of chemotherapy in clinical and rational development of chemotherapy regimens.